Multiple lines of evidence demonstrate that the noradrenergic system provides both direct and indirect excitatory drive onto midbrain dopamine (DA) neurons. We used DA b-hydroxylase (DBH) knockout (DbhÀ/À) mice that lack norepinephrine (NE) to determine the consequences of chronic NE deficiency on midbrain DA neuron function in vivo. Basal extracellular DA levels were significantly attenuated in the nucleus accumbens (NAc) and caudate putamen (CP), but not prefrontal cortex (PFC), of DbhÀ/À mice, while amphetamine-induced DA release was absent in the NAc and attenuated in the CP and PFC. The decrease in dopaminergic tone was associated with a profound increase in the density of high-affinity state D 1 and D 2 DA receptors in the NAc and CP, while DA receptors in the PFC were relatively unaffected. As a behavioral consequence of these neurochemical changes, DbhÀ/À mice were hypersensitive to the psychomotor, rewarding, and aversive effects of cocaine, as measured by locomotor activity and conditioned place preference. Antagonists of DA, but not 5-HT, receptors attenuated the locomotor hypersensitivity to cocaine in DbhÀ/À mice. As DBH activity in humans is genetically controlled and the DBH inhibitor disulfiram has shown promise as a pharmacotherapy for cocaine dependence, these results have implications for the influence of genetic and pharmacological DBH inhibition on DA system function and drug addiction.
INTRODUCTION
Brainstem noradrenergic neurons project both directly and indirectly to midbrain dopamine (DA) neurons, where they regulate firing patterns and DA release (Swanson and Hartman, 1975; Jones and Moore, 1977; Darracq et al, 1998; Ventura et al, 2003; Liprando et al, 2004) . DA b-hydroxylase (DBH) controls norepinephrine (NE) production and the NE/DA ratio in noradrenergic neurons and modulates the activity of the DA system and certain psychostimulant-induced behaviors. This pathway has recently become of particular interest for three reasons: (1) a common, single-base polymorphism in the human Dbh gene that controls DBH enzymatic activity has been identified (Zabetian et al, 2001) ; (2) DBH activity affects responses to cocaine in humans, and recent studies indicate that the DBH inhibitor disulfiram has efficacy as a treatment for cocaine dependence (Carroll et al, 1998 (Carroll et al, , 2004 Cubells et al, 2000; George et al, 2000; Petrakis et al, 2000) ; and (3) Dbh knockout (DbhÀ/À) mice have changes in DA receptor signaling and are hypersensitive to the psychomotor effects of amphetamine (Weinshenker et al, 2002) . Therefore, it is of interest to understand the influence of DBH and the noradrenergic system on DA neuron function.
The psychostimulants cocaine and amphetamine facilitate release and/or block reuptake of DA, NE, and 5-HT, resulting in increased synaptic availability of these neurotransmitters. The mesolimbic and mesocortical DA systems, comprised of projections from the VTA to the nucleus accumbens (NAc) and prefrontal cortex (PFC), respectively, have been primarily implicated in both the reinforcing and aversive effects of these drugs of abuse (Koob et al, 1998; Spanagel and Weiss, 1999) . While DA pathways and signaling have been the focus of most psychostimulant addiction research, it is also clear that NE plays an important role in modulating responses to psychostimu-lants. For example, lesions of noradrenergic neurons, administration of the a 1 -adrenoreceptor (a 1 AR) antagonist prazosin, or targeted disruption of the a 1B AR attenuate the psychomotor effects of psychostimulants in rodents (Snoddy and Tessel, 1985; Mohammed et al, 1986; Darracq et al, 1998; Drouin et al, 2002a, b) . Paradoxically, we found that Dbh knockout (DbhÀ/À) mice are hypersensitive to the psychomotor effects of amphetamine (Weinshenker et al, 2002) , indicating that differences exist between chronic NE deficiency and disruption of a single adrenergic receptor or relatively acute losses of NE signaling. In addition, amphetamine-induced accumbal DA release and place preference are lost in mice with NE depletion in the PFC, suggesting that psychostimulant reward depends on a functional noradrenergic system (Ventura et al, 2003) .
As the noradrenergic system has a facilitory effect on DA neurons, we hypothesized that DA release would be compromised in DbhÀ/À mice and that a compensatory increase in DA receptor signaling might underlie the hypersensitivity of DbhÀ/À mice to amphetamine. To identify neurochemical changes associated with the amphetamine hypersensitivity in DbhÀ/À mice, we assessed DA release by microdialysis and high-affinity state DA receptors by radioligand binding in vitro. To further explore the effects of chronic DBH inhibition and NE deficiency on behavioral responses to psychostimulants, we tested cocaine-induced locomotion, reward, and aversion.
MATERIALS AND METHODS

Mouse Breeding and Genotyping
DbhÀ/À mice, maintained on a mixed 129/SvEv and C57BL/ 6J background, were developed and generated as described (Thomas et al, 1995 (Thomas et al, , 1998 . DbhÀ/À males were bred to Dbh + /À females. Pregnant Dbh + /À mice were given the AR agonists isoproterenol and phenylephrine (20 mg/ml each) + vitamin C (2 mg/ml) from E9.5-E14.5, and L-3,4-dihydroxyphenylserine (DOPS; 2 mg/ml + vitamin C 2 mg/ ml) from E14.5 to birth in their drinking water to rescue the embryonic lethality associated with the homozygous DbhÀ/À mutation. Owing to this treatment, NE and epinephrine were present in DbhÀ/À animals before but not after birth. DbhÀ/À mice were identified by the delayed growth and ptosis phenotypes, which are 100% correlated with the DbhÀ/À genotype. Genotypes were confirmed by PCR. Dbh + /À mice were used as controls because they have normal catecholamine levels and are indistinguishable from Dbh + / + mice for all previously tested phenotypes (Thomas et al, 1995 (Thomas et al, , 1998 . All mice were reared in a specific pathogen-free facility with a 12 h light/dark cycle (lights on at 0700 h, lights off at 1900 h); food and water were available ad libitum. Naïve mice between 3 and 6 months of age were used for all experiments. Both male and female mice were used for all experiments. No sex differences were observed, and results were combined.
Experimental protocols were approved by the animal care committee at Emory University, and meet the guidelines of the American Association for Accreditation of Laboratory Animal Care and Italian national law (DL no. 116, 1992) governing the use of animals for research.
Locomotor Activity
Experiments were conducted in an isolated behavior room between 1000 and 1600 h. Ambulations (consecutive beam breaks) were measured in transparent plexiglass cages (40 Â 20 Â 20 cm 3 ) placed into a rack with seven infrared photobeams spaced 5 cm apart, each end beam 5 cm from the cage wall (San Diego Instruments Inc., LaJolla, CA). Mice were placed in the activity chambers for 4 h, injected with cocaine (5, 10, or 20 mg/kg i.p.; Sigma-Aldrich, St Louis, MO), and ambulations were recorded for an additional 2 h. Data were analyzed by ANOVA followed by Bonferroni post-hoc tests. For the antagonist studies, saline, the 5-HT 1A antagonist WAY100635 (0.03 mg/kg), the 5-HT 2 antagonist ketanserin (0.3 mg/kg), the D 1 antagonist SCH23390 (0.03 mg/kg), or the D 2 antagonist eticlopride were injected i.p. 30 min prior to cocaine (20 mg/kg). Antagonist doses were chosen based on the literature and our pilot experiments; higher doses were tried, but typically resulted in sedation and ataxia, indicating nonspecific effects. All drugs were purchased from Sigma-Aldrich (St Louis, MO).
Radioligand Binding
Mice were euthanized by CO 2 asphyxiation, and brains were quickly removed and dissected on ice. Dissections were guided by the mouse brain atlas (Paxinos and Franklin, 1997) . The frontal cortex was isolated by removing the olfactory bulb and making a cut 1 mm caudal to the beginning of the brain proper. As this region is comprised mostly of PFC and related structures, it will be subsequently referred to as the PFC. The striatum was isolated by making a second cut 1.5 mm caudal to the first cut, then cutting away the cortex, the most medial structures including the septum and diagonal band, and the most ventral structures including the olfactory tubercle and ventral pallidum. Each remaining hemisphere was then cut horizontally just above the anterior commmissure to isolate the dorsal striatum caudate putamen (CP) and NAc. Brain tissue was then placed in microfuge tubes, frozen on dry ice, and stored at À701C until used. As B30 mg of tissue was required for each assay, tissue from eight mice per genotype was batched.
D 2 receptor radioligand binding experiments were performed as described (Seeman et al, 2002) . Briefly, tissue was homogenized in buffer (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl 2 ) with or without 200 mM guanilylimidodiphosphate (guanine nucleotide (GN)), and placed in glass test tubes, followed by the addition of [ 3 H]raclopride (76.8 Ci/mmol; 12 final concentrations, from 0.2 to 20 nM). Samples were incubated at room temperature and passed through a filter, which was then rinsed, placed in vials of scintillant, and monitored 6 h later for tritium using a spectrometer. Nonspecific binding for D 2 receptors was defined as that which occurred in the presence of 10 mM S-sulpiride (Ravizza, Milan, Italy . Each binding assay was performed three times on separate days, and the absolute values for the total receptor densities varied 5-8% from day to day. Therefore, it was more reliable to measure the difference caused by GN on the receptor density in the Dbh + /À and DbhÀ/À samples on the same day. This procedure permitted the reliable detection of differences in DA receptor densities which ranged from 0.7 to 11.7 pmol/g for D 1 and from 0.4 to 10.3 pmol/g for D 2 . The net difference caused by GN varied by less than 10% for the triplicate experiments.
Microdialysis
Upon their arrival, animals were housed in groups of four in standard breeding cages (27 Â 21 Â 13.5 cm 3 ), with food and water ad libitum on a 12/12 h dark/light cycle (light on between 0700 and 1900 h). All mice used were handled and accustomed to the environment where the experiment was to be performed and then randomly assigned to different treatments. All experiments were carried out between 1400 and 1800 h.
Animals were anesthetized with chloral hydrate (450 mg/ kg), mounted in a stereotaxic frame (David Kopf Instruments, Tujunga, CA) equipped with a mouse adapter, and implanted unilaterally with a guide cannula (stainless steel, shaft OD 0.38 mm, Metalant AB, Stockholm, Sweden) in the CP, NAc, or PFC. The length of the guide cannula was: 2.5 mm for the CP, 4 mm for the NAc, and 1 mm for the PFC. The guide cannula was fixed with epoxy glue, and dental cement was added for further stabilization. The coordinates from bregma, measured in mm according to the mouse brain atlas (Paxinos and Franklin, 1997) , were: + 1.0 anteroposterior and + 1.4 lateral for the CP, + 1.4 anteroposterior and + 0.6 lateral for the NAc (mostly including the shell subdivision; Paxinos and Franklin, 1997; Ventura et al, 2003) , and + 2.52 anteroposterior and 0.6 lateral for the PFC. The probe (dialysis membrane length 2 mm for CP and PFC and 1 mm for NAc; o.d. 0.24 mm, MAB 4 cuprophane microdialysis probe, Metalant AB) was introduced 24-48 h after implantation of the guide cannula. The animals were lightly anesthetized with chloral hydrate (225 mg/kg) to facilitate manual insertion of the microdialysis probe into the guide cannula. The membranes were tested for in vitro recovery of DA on the day before use in order to verify recovery.
The microdialysis probe was connected to a CMA/100 pump (Carnegie Medicine, Stockholm, Sweden) through PE-20 tubing and an ultra-low torque dual-channel liquid swivel (Model 375/D/22QM, Instech Laboratories, Inc., Plymouth Meeting, PA) to allow free movement. Artificial CSF (147 mM NaCl, 2.2 mM CaCl 2 and 4 mM KCl) was pumped through the dialysis probe at a constant flow rate of 2 ml/min. Experiments were carried out 22-24 h after probe placement. Each animal was placed in a circular cage (21.5 cm in height, 17.5 cm in diameter) provided with microdialysis equipment (Instech Laboratories, Inc.) and with home cage bedding on the floor. Dialysis perfusion was started 1 h later. Following the start of dialysis perfusion, mice were left undisturbed for approximately 2 h before the collection of baseline samples. Following baseline sample collection (1 sample every 20 min for 60 min), mice were injected with saline or amphetamine (2.5 mg/kg, i.p.), and dialysate was collected every 20 min for 120 min. Only data from mice with correctly placed cannula (judged by methylene blue staining) were reported. In all, 20 ml of the dialysate samples was analyzed by high-performance liquid chromatography (HPLC). The remaining 20 ml was kept for possible subsequent analysis. Concentrations (pg/20 ml) were not corrected for probe recovery. The mean concentration of the three samples collected immediately before treatment (less than 10% variation) was taken as basal concentration.
The HPLC system consisted of an Alliance (Waters Corporation, Milford, MA) system and a coulometric detector (ESA Model 5200A Coulochem II) provided with a conditioning cell (M 5021) and an analytical cell (M 5011). The conditioning cell was set at 400 mV, electrode 1 at 200 mV, and electrode 2 at À250 mV. A Nova-Pack C18 column (3.9 Â 150 mm, Waters) maintained at 331C was used. The flow rate was 1.1 ml/min. The mobile phase was as described previously (Ventura et al, 2003) . The assay detection limit was 0.1 pg.
Statistical analyses were performed on raw data (concentrations, pg/20 ml). The effects of amphetamine on extracellular monoamine levels in the CP, NAc, or PFC were analyzed by repeated-measures ANOVA with two between-factor (strain, two levels: Dbh + /À and DbhÀ/À; treatment, two levels: amphetamine and saline) and one within-factor (minutes, seven levels: 0, 20, 40, 60, 80, 100, and 120). Simple effects were assessed by one-way ANOVA for each time point. Individual between-group comparisons, when appropriate, were performed by post-hoc test (Duncan's multiple range test).
Conditioned Place Preference
Experiments were conducted in an isolated behavior room between 1000 and 1600 h. Mice were placed in the 'neutral' middle compartment of a three-compartment conditioned place preference chamber (San Diego Instruments, La Jolla, CA) and allowed to freely explore the other two compartments that were distinguishable by floor texture and wall pattern for 20 min, and time spent in each compartment was recorded ('pretest'). After 1-6 days, mice were subjected to 'conditioning' sessions for three consecutive days. Mice were given an injection of saline (10 ml/kg, i.p.) and restricted to one compartment for 30 min in the morning, then given an i.p. injection of saline or cocaine (5, 10, 20, 40, or 60 mg/kg, 10 ml/kg) and restricted to the other compartment for 30 min in the afternoon (B4 h after the morning conditioning session). Mice were designated to receive cocaine on either the 'A' side or 'B' side using an unbiased design (ie for each genotype, equal numbers of mice received cocaine on each side, and equal numbers of mice received cocaine on the 'preferred' side and 'nonpreferred' side based on pretest results). The day following the last conditioning session, mice were placed in the neutral middle compartment in a drug-free state, allowed to freely explore all compartments for 20 min, and time spent in each compartment was recorded. Testing sessions were begun roughly halfway between the morning and afternoon conditioning sessions of the third day of conditioning. The preference score was calculated by subtracting the amount of time spent on the saline-paired side from the amount of time spent on the cocaine-paired side. Data were analyzed by paired t-tests (pretest preference vs post-test preference for each group).
RESULTS
Basal and Amphetamine-Induced DA Release is Attenuated in DbhÀ/À Mice As the activity of mesolimbic dopaminergic neurons is enhanced by NE, we predicted that striatal DA release would be compromised in DbhÀ/À mice. We assessed DA release in the NAc, CP, and PFC of awake, behaving Dbh + /À and DbhÀ/À mice by microdialysis. Basal extracellular DA levels were significantly reduced in the NAc and CP, but not the PFC, of DbhÀ/À mice (NAc: Dbh + /À 1.2570.25 pg/20 ml, DbhÀ/À 0.5670.5, Po0.05; CP: Dbh + /À 1.9970.27, DbhÀ/À 1.3270.11, Po0.05; PFC: Dbh + /À 0.5670.03, DbhÀ/À 0.4770.03). Basal extracellular NE levels were 1.0270.13 in the PFC and 0.6270.09 in the NAc of Dbh + /À mice, while NE was undetectable in DbhÀ/À mice.
The effects of amphetamine on DA release are shown in Figure 1 . Extracellular DA levels in the NAc, CP, and PFC of Dbh + /À mice were increased dramatically by amphetamine administration (2.5 mg/kg, i.p.), peaking at B100% maximal increase in the NAc and CP and B200% maximal increase in the PFC. In contrast, the amphetamine-induced increase in extracellular DA was absent in the NAc, and present but reduced in the CP (50% maximal increase) and PFC (75% maximal increase) of DbhÀ/À mice. Statistical analyses revealed a significant strain Â treatment Â minutes interaction for the NAc (F 6,226 ¼ 3.44; Po0.005), CP (F 6,120 ¼ 2.23; Po0.05), and PFC (F 6,114 ¼ 2.30; Po0.05). Post hoc analysis revealed significant differences between Dbh + /À and DbhÀ/À mice challenged with amphetamine at multiple time points (Figure 1 ).
Increased Density of Striatal High-Affinity State DA Receptors in DbhÀ/À Mice Reductions in striatal DA availability typically result in the upregulation of striatal DA receptors. In addition, DbhÀ/À mice share a number of phenotypes with wild-type animals that have undergone psychostimulant sensitization, including greater psychostimulant-and D 2 agonist-induced locomotion, and an increase in striatal high-affinity state D 2 receptors is thought to contribute to these phenotypes in sensitized animals (Seeman et al, 2002 (Seeman et al, , 2005 et al, 2002). We measured saturation binding of the D 1 antagonist SCH23390 and the D 2 antagonist raclopride to brain tissue homogenates in the presence and absence of GN. Under normal conditions, antagonist binding to highaffinity state receptors is prevented by endogenous DA, but previous data are consistent with the principle that GN permits the release of receptor-bound DA and allows the binding of the antagonist to all receptors (Seeman et al, 1989) . Thus, the difference in antagonist binding in the presence and absence of GN represents the density of highaffinity state receptors.
While no large differences in total striatal DA receptors were found between Dbh + /À and À/À mice, high-affinity state DA receptors were markedly elevated in DbhÀ/À mice (D 1 receptors: 1.9 pmol/g for Dbh + /À mice, 5.7 pmol/g for DbhÀ/À mice in the CP; 6.6 pmol/g for Dbh + /À mice, 11.7 pmol/g for DbhÀ/À mice in the NAc; D 2 receptors: 3.7 pmol/g for Dbh + /À mice, 10.3 pmol/g for DbhÀ/À mice in the CP; 0.8 pmol/g for Dbh + /À mice, 5.3 pmol/g for DbhÀ/À mice in the NAc; Figure 2a- Seeman et al, 2005) . In contrast, the density of high-affinity state DA receptors in the PFC of DbhÀ/À mice was similar to that of controls (D 1 receptors: 0.7 pmol/g for Dbh + /À mice, 0.7 pmol/g for DbhÀ/À mice; D 2 receptors: 0.4 pmol/g for Dbh + /À mice, 0.6 pmol/g for DbhÀ/À mice, and total D 2 receptor density was modestly reduced (Figure 2e and f) .
DbhÀ/À Mice are Hypersensitive to Cocaine-Induced Locomotion
We have previously shown that DbhÀ/À mice are hypersensitive to amphetamine-induced locomotion and stereotypy (Weinshenker et al, 2002) . To determine whether this hypersensitivity extends to cocaine, we measured the locomotor response of Dbh + /À and DbhÀ/À mice to cocaine. Cocaine produced a dose-dependent increase in locomotor activity in both Dbh + /À and À/À mice ( Figure 3) . However, as with amphetamine, cocaine-induced locomotion was greater in DbhÀ/À mice at all doses tested; there was a significant genotype Â time interaction for 5 mg/kg (F 11,168 ¼ 6.82, Po0.0001), 10 mg/kg (F 11,168 ¼ 8.80, Po0.0001), and 20 mg/kg cocaine (F 11,144 ¼ 5.52, Po0.0001). Post hoc analysis revealed significant differences between DbhÀ/À mice are hypersensitive to cocaine JR Schank et al Dbh + /À and DbhÀ/À mice at multiple time points following cocaine administration (Figure 3 ). Locomotor activity in response to a novel environment prior to drug administration was reduced in DbhÀ/À mice, as described previously (Weinshenker et al, 2002; Figure 3) .
To determine whether the alterations in DA receptors contributed to the locomotor hypersensitivity of DbhÀ/À mice to cocaine, saline, the D 1 antagonist SCH23390, or the D 2 antagonist eticlopride were administered to mice 30 min prior to cocaine (20 mg/kg). As serotonergic hyperinnervation of the striatum can occur after DA depletion, we also tested the ability of 5-HT antagonists to prevent the cocaine hypersensitivity of DbhÀ/À mice. A significant effect of treatment was found for both genotypes (one-way ANOVA: Dbh + /À F 5,49 ¼ 4.35, Po0.0001; DbhÀ/À F 5,48 ¼ 12.03, Po0.0001). Post hoc analysis revealed that both SCH23390 and eticlopride attenuated cocaine-induced locomotion in Dbh + /À and DbhÀ/À mice (Figure 4) . In contrast, the 5-HT 1A antagonist WAY100635 and the 5-HT 2 antagonist ketanserin attenuated cocaine-induced locomotion in Dbh + /À mice, but were completely without effect in DbhÀ/À mice (Figure 4 ).
Altered Cocaine Reward and Aversion in DbhÀ/À Mice
To determine whether the alterations of dopaminergic signaling in DbhÀ/À mice affect psychostimulant reward, we assessed cocaine conditioned place preference in Dbh + /À and DbhÀ/À mice. The side preference of both genotypes before pairing with cocaine and after pairing with saline was essentially random (Figure 5 ). While Dbh + /À mice expressed a significant place preference to cocaine at the moderate and high dose (10 and 20 mg/kg) but not the low dose (5 mg/kg), DbhÀ/À mice expressed a significant preference only at the low dose and avoided the cocainepaired chamber at the high dose ( Figure 5 ). To determine whether the normal dose response to cocaine was shifted in DbhÀ/À mice, we examined whether higher doses of cocaine produced a place aversion in Dbh + /À mice. Conditioned place aversion was not observed in Dbh + /À using cocaine doses up to 60 mg/kg, the highest dose tested ( Figure 5 ). Dbh + /À mice in fact showed a trend towards a place preference at 40 and 60 mg/kg cocaine, but it was not quite significant in either case (post-test preference for cocaine-paired side at 40 mg/kg: + 3277178 s, P ¼ 0.1 compared to pretest, N ¼ 10; 60 mg/kg: + 2487245 s, P ¼ 0.21 compared to pretest, N ¼ 9).
DISCUSSION
Regulation of DA Release by NE
We found that basal extracellular DA levels were attenuated in the NAc and CP of DbhÀ/À mice. Consistent with these results, LC lesions decrease striatal DA availability (Russell et al, 1989; Lategan et al, 1990 Lategan et al, , 1992 Haidkind et al, 2002) , resulting in DA receptor supersensitivity (Donaldson et al, 1976; Lategan et al, 1989; Harro et al, 2000) . Basal DA release in the PFC was not significantly affected, suggesting that NE is more critical for the basal tone of mesolimbic and nigrostriatal DA neurons than for mesocortical DA neurons. However, it is important to note that the NE transporter (NET) can take up DA, and noradrenergic neurons may release DA as well as NE (Carboni and Silvagni, 2004; Devoto et al, 2005) . Therefore, it is possible that basal DA levels in the PFC of DbhÀ/À mice are maintained by the local release of DA from 'noradrenergic' neurons. This 'ectopic' DA could be synthesized de novo by the 'noradrenergic' neurons or be released from dopaminergic terminals and taken up into the noradrenergic neurons via the NET.
Amphetamine can increase DA release in an impulseindependent manner by acting directly on DA transporters. However, accumbal DA release following systemic amphetamine appears to be primarily impulse-dependent in some mouse strains, and NE is critical for this aspect of DA outflow (Ventura et al, 2004) . Amphetamine-induced burst firing of DA neurons is dependent on a 1 AR signaling, and amphetamine-induced DA release in the NAc is attenuated in a 1B AR knockout mice, mice with depletion of NE in the PFC, and by a 1 AR antagonists (Darracq et al, 1998; Shi et al, 2000; Paladini et al, 2001; Auclair et al, 2002; Ventura et al, 2003) . Our data confirm and extend these findings. Amphetamine-induced DA release was completely abolished in the NAc of DbhÀ/À mice, while DA release persisted in the CP and PFC, although at reduced levels. These results indicate that NE is required for the maximal increase in extracellular DA observed after psychostimulant administration, and that mesolimbic DA neurons absolutely depend on the noradrenergic system for this response.
The LC, A1, and A2 brainstem cell groups project directly to the VTA and exert excitatory control over DA neuron firing (Jones and Moore, 1977; Simon et al, 1979; Grenhoff et al, , 1995 Liprando et al, 2004; Mejias-Aponte et al, 2004) . In addition, PFC neurons express a 1 ARs (Palacios et al, 1987; Pieribone et al, 1994) , and a 1 AR antagonists infused directly into the PFC or NE depletion in the PFC attenuate amphetamine-induced DA release in the NAc (Darracq et al, 1998; Ventura et al, 2003) . Thus, the lack of both 'direct' and 'indirect' (via the PFC and other structures; Taber et al, 1995; Tong et al, 1996; Marek and Aghajanian, 1999; Carr and Sesack, 2000; Darracq et al, 2001 ) excitatory noradrenergic inputs to the VTA likely contributes to the reduction of accumbal DA release in DbhÀ/À mice.
DA Receptor Supersensitivity in DbhÀ/À Mice
A reduction in DA availability typically results in the upregulation of DA receptor signaling in terminal regions. For example, DA receptor hypersensitivity is observed after lesions of DA neurons (Arnt, 1985) or genetic DA depletion (Kim et al, 2000) . An increase in high-affinity state DA receptors was observed in the NAc and CP, but not the PFC, of DbhÀ/À mice. As DA availability in the PFC of DbhÀ/À mice was normal under basal conditions but decreased after amphetamine administration, the increase in striatal highaffinity state receptors correlated with the basal availability of extracellular DA, as opposed to the availability of DA after evoked release. Although the density of both highaffinity state D 1 and D 2 receptors was increased in the striatum, DbhÀ/À mice were hypersensitive to the behavioral effects of a D 2 agonist, but not a D 1 agonist; in fact, DbhÀ/À mice are relatively insensitive to D 1 agonistinduced locomotion (Weinshenker et al, 2002) . As D 1 signaling in the PFC opposes DA release in the NAc and locomotor activation (Vezina et al, 1991; Ventura et al, 2004) , PFC D 1 receptors may be preferentially activated by D 1 agonists in DbhÀ/À mice, although other explanations are possible.
Taken together, these neurochemical changes in DA signaling may explain the behavioral hypersensitivity of DbhÀ/À mice to amphetamine. We have previously shown that amphetamine-induced locomotion is modestly enhanced in DbhÀ/À mice, while amphetamine-induced stereotypy is greatly magnified (Weinshenker et al, 2002) . DA signaling in the CP is thought to underlie stereotypies. For example, a number of groups have shown that 6-OHDA lesions of the CP abolish amphetamine-induced stereotypy (Kelly et al, 1975; Makanjuola and Ashcroft, 1982) . Thus, the persistence of some amphetamine-induced DA release in the CP of DbhÀ/À mice coupled with the profound striatal DA receptor hypersensitivity likely underlies their stereotypy-related phenotypes. In contrast, the locomotor response to amphetamine has been attributed to DA signaling in the NAc (eg Kelly et al, 1975; Pijnenburg et al, 1975; Makanjuola and Ashcroft, 1982) , and it might seem surprising that amphetamine-induced locomotion is intact in DbhÀ/À mice despite a lack of amphetamineinduced DA release in the NAc. As the locomotor response to amphetamine is blocked by DA antagonists in DbhÀ/À mice (Weinshenker et al, 2002) , we speculate that DA release in other brain regions, such as the CP and/or PFC, is responsible. This is consistent with the work of Ventura et al (2003) , who demonstrated that amphetamine-induced locomotion can occur in the absence of DA release in the NAc. Alternatively, DA release in the NAc of DbhÀ/À mice may occur at levels below our limit of detection, yet be sufficient for locomotor behavior due to receptor hypersensitivity.
Chronic Dbh Deficiency Affects Cocaine Locomotion, Reward, and Aversion
Our results indicate that, similar to amphetamine, DbhÀ/À mice are hypersensitive to cocaine-induced locomotion. We assessed the effects of DA and 5-HT antagonists to determine whether the hypersensitivity was mediated by DA and/or 5-HT receptors. WAY100635 and ketanserin were used for three reasons. First, 5-HT 1A and 5-HT 2 receptors modulate DA release and cocaine-induced locomotion in rats (De Deurwaerdère and Spampinato, 1999; Carey et al, 2001; Broderick et al, 2004) . Second, serotonergic hyperinnervation of the striatum occurs after DA neuron lesions, and these receptors contribute to the hyperlocomotion observed in monoamine-depleted animals (Stachowiak et al, 1984; Mignon and Wolf, 2002; Zhang et al, 2002; Bishop et al, 2003) . Third, the residual locomotor response to psychostimulants in a 1B knockout mice is mediated by compensatory 5-HT 2A signaling (Auclair et al, 2004) . We found that cocaine-induced locomotion in Dbh + /À mice was attenuated by DA and 5-HT antagonists, but only the DA antagonists effectively eliminated cocaine-induced locomotion in DbhÀ/À mice. We conclude that the expression of cocaine hypersensitivity of DbhÀ/À mice is mediated by changes in DA receptors, although changes in 5-HT signaling could contribute to the development of the hypersensitivity.
Interestingly, acute pharmacological inhibition of DBH or a 1 ARs has the opposite effect of chronic DBH deficiency; a single injection of the DBH inhibitor disulfiram or the a 1 AR antagonist prazosin attenuated psychostimulant-induced locomotion (Maj et al, 1968; Darracq et al, 1998; Weinshenker et al, 2002) . In contrast, chronic disulfiram administration increases cocaine sensitization (Haile et al, 2003) . These observations indicate that the dopaminergic adaptations in response to the chronic absence of NE, and not the acute lack of NE, underlie the psychostimulant hypersensitivity of DbhÀ/À mice.
Psychostimulants possess both rewarding and aversive properties. The conditioned place preference (CPP) of DbhÀ/À mice to a low dose of cocaine that does not support a CPP in Dbh + /À mice suggests a hypersensitivity to cocaine reward. Perhaps the most striking phenotype we observed was the aversion of DbhÀ/À mice to a dose of cocaine (20 mg/kg) that produced a place preference in control mice. We attempted to produce a place aversion in control mice by increasing the dose of cocaine used during the conditioning sessions. Even at the highest dose tested (60 mg/kg), Dbh + /À mice still tended to prefer the cocainepaired side. We did not test higher doses because 60 mg/kg is near the threshold for cocaine-induced seizures in mice, which would confound the results (eg Golden et al, 2001) . Thus, it is not technically correct to say that chronic Dbh deficiency produces hypersensitivity to the cocaine place aversion, because the phenotype was never observed in control mice. Rather, there appears to be a novel shift in the balance between cocaine reward and aversion in DbhÀ/À mice, where the aversive properties of cocaine can become overwhelming and preclude the reward (Ettenberg and Geist, 1991) . Importantly, no seizure activity was observed in DbhÀ/À mice following administration of the cocaine dose (20 mg/kg) that produced the place aversion. To our knowledge, this is one of the only examples of a conditioned place aversion to cocaine in rodents. Both a lack of NE and hyperdopaminergic signaling could contribute to this phenotype. For example, mice specifically lacking NE in the PFC show a similar place aversion to amphetamine (Ventura et al, 2003) , and DbhÀ/À mice are hypersensitive to the aversive effects of ethanol (Weinshenker et al, 2000) . In addition, because DA release occurs in response to aversive as well as rewarding events (Thierry et al, 1976; Abercrombie et al, 1989; Jensen et al, 2003) and DbhÀ/À mice have hypersensitive DA receptors, excessive DA signaling may also underlie the aversion.
DBH and Cocaine Dependence
DBH activity varies between individuals, and this variation has a strong genetic component that is primarily controlled by a single, common polymorphism (Zabetian et al, 2001) . Our results suggest that dopaminergic function and psychostimulant responses could be altered in individuals with low DBH activity, a hypothesis that is supported by the human literature. For instance, cocaine-induced paranoia is more prevalent in individuals with genetically low DBH activity (Cubells et al, 2000) . Furthermore, the DBH inhibitor disulfiram has shown promise as a treatment for cocaine dependence (Carroll et al, 2004) . These findings suggest that genetic or pharmacological inhibition of DBH may increase the aversive effects of cocaine.
